News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
327,555 Results
Type
Article (19581)
Company Profile (139)
Press Release (307835)
Section
Business (105177)
Career Advice (867)
Deals (18492)
Drug Delivery (90)
Drug Development (50622)
Employer Resources (79)
FDA (7632)
Job Trends (7719)
News (185485)
Policy (17293)
Tag
Academia (726)
Alliances (27688)
Alzheimer's disease (561)
Approvals (7600)
Artificial intelligence (81)
Bankruptcy (170)
Best Places to Work (5508)
Biosimilars (67)
Biotechnology (62)
Cancer (545)
Cardiovascular disease (60)
Career advice (704)
Cell therapy (83)
Clinical research (41730)
Collaboration (213)
Compensation (69)
COVID-19 (1073)
C-suite (60)
Data (620)
Diabetes (94)
Diagnostics (1716)
Drug pricing (91)
Earnings (38282)
Employer resources (73)
Events (47585)
Executive appointments (199)
FDA (7893)
Funding (156)
Gene therapy (87)
GLP-1 (485)
Government (1797)
Healthcare (5853)
Infectious disease (1121)
Inflammatory bowel disease (67)
Interviews (114)
IPO (7291)
Job creations (2431)
Job search strategy (645)
Layoffs (252)
Legal (4078)
Lung cancer (96)
Manufacturing (128)
Medical device (1959)
Medtech (1962)
Mergers & acquisitions (11239)
Metabolic disorders (326)
Neuroscience (725)
NextGen Class of 2024 (2348)
Non-profit (902)
Northern California (668)
Obesity (210)
Opinion (174)
Patents (70)
People (32897)
Pharmaceutical (75)
Phase I (13000)
Phase II (17663)
Phase III (14224)
Pipeline (283)
Podcasts (56)
Policy (70)
Postmarket research (1610)
Preclinical (4563)
Radiopharmaceuticals (157)
Rare diseases (138)
Real estate (3164)
Regulatory (12121)
Research institute (816)
Resumes & cover letters (138)
Southern California (615)
Startups (2005)
United States (6123)
Vaccines (211)
Weight loss (184)
Date
Today (45)
Last 7 days (330)
Last 30 days (1820)
Last 365 days (17956)
2024 (16435)
2023 (19636)
2022 (25870)
2021 (26645)
2020 (24875)
2019 (20064)
2018 (15595)
2017 (17257)
2016 (16202)
2015 (18804)
2014 (14788)
2013 (12553)
2012 (13484)
2011 (13818)
2010 (12739)
Location
Africa (406)
Asia (24453)
Australia (3147)
California (1500)
Canada (747)
China (147)
Colorado (64)
Connecticut (60)
Europe (50460)
Florida (212)
Illinois (146)
Indiana (115)
Japan (56)
Maryland (228)
Massachusetts (1266)
Minnesota (88)
New Jersey (580)
New York (439)
North Carolina (357)
Northern California (668)
Ohio (63)
Pennsylvania (371)
South America (603)
Southern California (615)
Texas (197)
Washington State (145)
327,555 Results for "eip pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. (“EIP”), and a reverse stock split of outstanding Diffusion Common Stock (the “Reverse Split”).
August 15, 2023
·
6 min read
Deals
CervoMed Announces Completion of Merger with EIP Pharma
CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced the closing of its previously announced merger with EIP Pharma Inc.
August 16, 2023
·
9 min read
Business
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
Poolbeg Pharma announces a change of Board role and the Remuneration Committee’s approval of the adoption of an Employee Performance Incentive Plan for a number of the key senior management, to align medium and long term objectives with those of shareholders and to encourage retention.
February 15, 2024
·
13 min read
Genetown
EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference
EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, announced that the Company’s senior management team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9 at 4:00 p.m. ET.
August 3, 2023
·
4 min read
Drug Development
EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies
EIP Pharma Inc. today announced that the first patient has been dosed in the Company’s RewinD-LB Phase 2b clinical trial of neflamapimod for the treatment of patients with dementia with Lewy bodies (DLB).
August 14, 2023
·
12 min read
Genetown
EIP Pharma to Present at JMP Securities Life Sciences Conference 2023
EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, announced that the Company’s senior management team will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 11:00 a.m. ET.
May 11, 2023
·
4 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Business
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
EIP Pharma Inc. and Diffusion Pharmaceuticals Inc., announced that the companies have entered into a definitive merger agreement for an all-stock transaction forming a publicly traded, combined company that will focus on the advancement of EIP Pharma’s pioneering pipeline of oral stress kinase inhibitors, including its lead drug candidate neflamapimod, which is currently being developed for the treatment of dementia with Lewy bodies.
March 30, 2023
·
14 min read
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
1 of 32,756
Next